ACM closes pharma probes over lack of evidence

ACM closes pharma probes over lack of evidence

The Dutch competition authority has closed three preliminary investigations into pharmaceutical companies due to a lack of evidence the drug manufacturers breached antitrust law by tying their services and charging excessive prices to healthcare providers.

Unlock unlimited access to all Global Competition Review content